Vaxcyte Inc PCVX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 11:18 AM EDT
65.16quote price arrow down-0.03 (-0.05%)
Volume
81,935
52 week range
44.20 - 82.04
Loading...
  • Open65.10
  • Day High65.74
  • Day Low64.99
  • Prev Close65.19
  • 52 Week High82.04
  • 52 Week High Date02/28/24
  • 52 Week Low44.20
  • 52 Week Low Date10/13/23

Key Stats

  • Market Cap7.087B
  • Shares Out108.76M
  • 10 Day Average Volume0.58M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change3.86

KEY STATS

  • Open65.10
  • Day High65.74
  • Day Low64.99
  • Prev Close65.19
  • 52 Week High82.04
  • 52 Week High Date02/28/24
  • 52 Week Low44.20
  • 52 Week Low Date10/13/23
  • Market Cap7.087B
  • Shares Out108.76M
  • 10 Day Average Volume0.58M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change3.86

RATIOS/PROFITABILITY

  • EPS (TTM)-4.22
  • P/E (TTM)-15.43
  • Fwd P/E (NTM)-14.88
  • EBITDA (TTM)-432.878M
  • ROE (TTM)-29.83%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Vaxcyte Inc

 

Profile

MORE
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also...
Carlos Paya M.D., Ph.D.
Independent Chairman of the Board
Grant Pickering
Chief Executive Officer, Co-Founder, Director
Andrew Guggenhime
President, Chief Financial Officer
James Wassil
Chief Operating Officer, Executive Vice President
Address
825 INDUSTRIAL ROAD, STE. 300
San Carlos, CA
94070
United States

Top Peers

SYMBOLLASTCHG%CHG
RVMD
Revolution Medicines Inc
37.34+0.09+0.24%
CYTK
Cytokinetics Inc
61.02-1.08-1.74%
CERE
Cerevel Therapeutics Holdings Inc
42.10-0.09-0.20%
IBRX
Immunitybio Inc
8.54+0.43+5.23%
VKTX
Viking Therapeutics Inc
71.15-2.49-3.38%